Hagan Introduces Long-Anticipated TREAT Act, Sans Progressive, Exceptional Approval
This article was originally published in The Pink Sheet Daily
Bill looks to expand accelerated approval rather than create new approval pathways, and also would reform conflict of interest rules for FDA advisory committees.
You may also be interested in...
Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed
At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.
FDA Conflict Of Interest Policy May Be Biggest Conflict Of PDUFA Reauthorization
Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say system needs reform.
Accelerated Approval Could Expand As Alternative To Progressive Approval
CDER Director Woodcock says agency should issue internal and external guidance to promote consistent use of the pathway.